for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cytokinetics, Inc.

CYTK.OQ

Latest Trade

11.18USD

Change

0.41(+3.81%)

Volume

145,770

Today's Range

10.86

 - 

11.32

52 Week Range

5.76

 - 

14.91

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.77
Open
10.90
Volume
145,770
3M AVG Volume
9.58
Today's High
11.32
Today's Low
10.86
52 Week High
14.91
52 Week Low
5.76
Shares Out (MIL)
58.68
Market Cap (MIL)
656.03
Forward P/E
-5.53
Dividend (Yield %)
--

Next Event

Q3 2019 Cytokinetics Inc Earnings Release

Latest Developments

More

Cytokinetics Inc says May Offer And Sell Additional Shares Of Co's Common Stock Of Up To $50 Million From Time To Time

Cytokinetics Says Q2 Loss Per Share $0.56

Millennium Management Reports 5.3% Passive Stake In Cytokinetics

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cytokinetics, Inc.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Industry

Biotechnology & Drugs

Contact Info

280 E Grand Ave

+1.650.6243000

http://cytokinetics.com/

Executive Leadership

Leonard Patrick Gage

Independent Chairman of the Board

Robert I. Blum

President, Chief Executive Officer, Director

Ching Jaw

Chief Financial Officer, Senior Vice President

David W. Cragg

Chief Human Resource Officer, Chief Administrative Officer

Fady Ibraham Malik

Executive Vice President - Research and Development

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

0.390

2017

-2.590

2018

-1.950

2019(E)

-1.978
Price To Earnings (TTM)
--
Price To Sales (TTM)
18.42
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-55.51
Return on Equity (TTM)
-49.37

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up